The role of toll-like receptor 4 in the development of endometriosis and the benefits of trastuzumab in the treatment of endometriosis: a rat model

Basit Öğe Kaydı
dc.contributor.authorKorun, Zeynep Ece Utkan
dc.contributor.authorKirici, Pinar
dc.contributor.authorElibol, Ebru
dc.contributor.authorKaplan, Selcuk
dc.contributor.authorKaracor, Talip
dc.date.accessioned2026-06-19T06:39:32Z
dc.date.available2026-06-19T06:39:32Z
dc.date.issued2025
dc.departmentMalatya Turgut Özal Üniversitesi
dc.description.abstractWe aimed to investigate TLR-4 receptor activity in the development of endometriosis and the effect of trastuzumab in experimentally induced endometriotic tissue via TLR-4 in this study. Twenty-eight female Wistar-Albino rats were divided into four groups: Group 1 (Control Group), Group 2 (Endometriosis Group), Group 3 (Endometriosis + Trastuzumab Group), and Group 4 (Trastuzumab Group). All animal tissue samples were collected. Histopathological, immunohistochemical, and biochemical analyses were performed. In histopathological analysis, there was a significant difference between Group 2 and other groups in terms of connective tissue edema, inflammation, hemorrhage, epithelial damage, and mast cell density. In immunohistochemical analysis with TLR-4, Group 2 exhibited strong staining. In biochemical analysis, it was found that there was a highly significant difference between Group 2 and Group 1 considering the Malondialdehyde (MDA) levels in plasma samples. There was no significant difference in terms of the MDA levels among other groups. Considering the glutathione levels in the plasma samples, it was found that there was a highly significant difference between Group 2 and Groups 3 and 4. Trastuzumab may play a role in the treatment of histopathological damage and fibrosis in experimentally induced endometriotic implants by showing anti-inflammatory and antiproliferative activity.
dc.identifier.doi10.1080/10520295.2025.2486451
dc.identifier.endpage136
dc.identifier.issn1052-0295
dc.identifier.issn1473-7760
dc.identifier.issue3
dc.identifier.orcid0000-0003-1349-1569
dc.identifier.orcid0000-0002-1595-569X
dc.identifier.pmid40260736
dc.identifier.scopus2-s2.0-105003264299
dc.identifier.scopusqualityQ2
dc.identifier.startpage129
dc.identifier.urihttps://doi.org/10.1080/10520295.2025.2486451
dc.identifier.urihttps://hdl.handle.net/20.500.12899/5642
dc.identifier.volume100
dc.identifier.wosWOS:001472301800001
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherTaylor & Francis Ltd
dc.relation.ispartofBiotechnic & Histochemistry
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WOS_20260612
dc.subjectAntioxidant Effect
dc.subjectEndometriosis
dc.subjectRat
dc.subjectTlr-4
dc.subjectTrastuzumab
dc.titleThe role of toll-like receptor 4 in the development of endometriosis and the benefits of trastuzumab in the treatment of endometriosis: a rat model
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu